On May 1, a volunteer for a clinical trial was injected with an inactivated vaccine against the new coronavirus of the Omicron variant strain in Hangzhou. Xinhua News Agency issuedOn the afternoon of May 1, the clinical study of the new coronavirus inactivated vaccine of Omicron variant developed by Sinopharm China Bio-Beijing Institute of Biological Products officially completed the first dose of vaccination in Hangzhou, Zhejiang Province. . This is also the world’s first inactivated vaccine against the new coronavirus that has entered clinical trials against the Ormicron variant.
Month 1 Test volunteers were injected with an inactivated vaccine against the new coronavirus of the Omicron variant strain in Hangzhou. Xinhua| Safety and immunogenicity in the population. After this clinical study data is approved, blank populations who have not been vaccinated against the new crown vaccine can be directly vaccinated with the Austrian strain vaccine.
Omicoron mutation developed by Sinopharm China Bio-Beijing Institute of Biological Products, photographed on April 22 New coronavirus inactivated vaccine. Xinhua News Agency issued “The development of vaccines for Omicron mutants is very important. Of course, the original vaccine is still effective, but after the development of vaccines for mutant strains, there may be better The immune effect.This also proves the speed and efficiency of China in the anti-epidemic work.” Li Lanjuan, academician of the Chinese Academy of Engineering, said that he believed that through rigorous clinical research, the safety and effectiveness of the vaccine will be improved. It can be further proved to ensure the application of vaccines in the future.
Source: Xinhua News Agency, Beijing Daily (Reporter: Yuan Lu)
Producer: Yu Weiya Editors: Li Ang, Wu Yue
Like!